eligibility_summary
Adults 18–75 with histologically/cytologically confirmed pancreatic cancer with liver-only metastasis deemed potentially resectable by MDT. No prior systemic therapy, willing for nimotuzumab-based conversion therapy, measurable disease (RECIST 1.1), adequate organ function, ECOG 0–1, life ≥3 months, contraception and consent. Exclude: refusal, extrahepatic mets, other cancers, serious comorbidities, recent major surgery or EGFR therapy, allergies, HIV/HPV/syphilis/active HBV/HCV, unresolved ≥G2 AEs, investigator judgment.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2, single-arm conversion-therapy study in pancreatic cancer with liver metastasis testing: 1) Nimotuzumab: humanized anti-EGFR monoclonal antibody (targeted immunotherapy) that blocks EGFR ligand binding and downstream signaling (RAS/RAF/MEK/ERK, PI3K/AKT), inhibiting proliferation and potentially inducing ADCC via NK cells. 2) Gemcitabine: antimetabolite nucleoside analog (chemotherapy) that inhibits ribonucleotide reductase and incorporates into DNA, halting S-phase DNA synthesis. 3) Nab-paclitaxel: albumin-bound taxane (chemotherapy) that stabilizes microtubules, causing mitotic arrest. Targets: EGFR-overexpressing pancreatic tumor cells, EGFR signaling pathways, DNA synthesis machinery in rapidly dividing cells, microtubule/mitotic spindle dynamics, innate immune effector engagement (NK cells). Primary endpoint: R0 resection rate.